This study is looking at a new medicine called disitamab vedotin to see if it works for a type of cancer called urothelial cancer that shows a protein called HER2. Urothelial cancer is a cancer that starts in the lining of the bladder or other parts of the urinary system. Disitamab vedotin might be given alone or with another medicine called pembrolizumab. The study will also check how safe the medicine is and what side effects it might cause. Side effects are changes in your body from the medicine that are not related to treating the cancer.

• The study may involve multiple visits to the research center and could last several months.
• Participants should have urothelial cancer that cannot be treated with surgery or has spread.
• Eligibility depends on previous treatments and general health status.

To join, participants need tests to confirm if their cancer shows HER2. They should also have a good health score according to the Eastern Cooperative Oncology Group (ECOG), which checks how well a person can do daily activities. Talk to your doctor to see if you qualify for the study.